PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
Background Few tissue biomarkers exist to date that could enrich patient with cancer populations to benefit from immune checkpoint blockade by programmed cell death protein 1/ligand-1 (PD-/L-1) inhibitors. PD-L1 expression has value in this context in some tumor types but is an imperfect predictor o...
Saved in:
Main Authors: | Solange Peters, Urania Dafni, Panagiota Zygoura, Sanjay Popat, Mary O'Brien, Rolf A Stahel, Alessandra Curioni-Fontecedro, Georges Coukos, Amy Roy, Riyaz Shah, Krisztian Homicsko, James Spicer, Stephen P Finn, David Gilligan, Maxim Norkin, Stephanie Tissot, Nicholas Shakarishvili, Anthony Pope, Patricia Fisher, Sylvie Rusakiewicz, Ekaterina Fortis, Nesa Marti, Roswitha Kammler |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-10-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/10/e007585.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gradient material Pd-PdHx
by: M. V. Goltsova, et al.
Published: (2018-10-01) -
Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01) -
Acoustic Analysis of PD Speech
by: Karen Chenausky, et al.
Published: (2011-01-01) -
Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
by: Chenyue Qian, et al.
Published: (2018-01-01) -
Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)